Department of Pharmacology of Zunyi Medical College and the Key Laboratory of Basic Pharmacology of Guizhou, Zunyi 563003, China.
Evid Based Complement Alternat Med. 2012;2012:314395. doi: 10.1155/2012/314395. Epub 2012 Mar 5.
Ginsenoside Rg1 (Rg1) has been reported to suppress the proliferation of vascular smooth muscle cells (VSMCs). This study aimed to observe the role of nitric oxide (NO) in Rg1-antiproliferative effect. VSMCs from the thoracic aorta of SD rats were cultured by tissue explant method, and the effect of Rg1 (20 mg·L(-1), 60 mg·L(-1), and 180 mg·L(-1)) on platelet-derived growth factor-BB (PDGF-BB)-induced proliferation was evaluated by MTT assay. The cell cycle was analyzed by flow cytometry. For probing the mechanisms, the content of NO in supernatant and cGMP level in VSMCs was measured by nitric oxide kit and cGMP radio-immunity kit, respectively; the expressions of protooncogene c-fos and endothelial NO synthase (eNOS) mRNA in the VSMCs were detected by real-time RT-PCR; the intracellular free calcium concentration (Ca2(+)) was detected with Fura-2/AM-loaded VSMCs. Comparing with that in normal group, Rg1 180 mg·L(-1) did not change the absorbance of MTT and cell percent of G(0)/G(1), G(2)/M, and S phase in normal cells (P > 0.05). Contrarily, PDGF-BB could increase the absorbance of MTT (P < 0.01) and the percent of the S phase cells but decrease the G(0)/G(1) phase cell percent in the cell cycle, accompanied with an upregulating c-fos mRNA expression (P < 0.01), which was reversed by additions of Rg1(20 mg·L(-1), 60 mg·L(-1), and 180 mg·L(-1)). Rg1 administration could also significantly increase the NO content in supernatant and the cGMP level in VSMCs, as well as the eNOS mRNA expression in the cells, in comparison of that in the group treated with PDGF-BB alone (P < 0.01). Furthermore, Rg1 caused a further increase in the elevated Ca(2+) induced by PDGF-BB. It was concluded that Rg1 could inhibit the VSMC proliferation induced by PDGF-BB through restricting the G(0)/G(1) phase to S-phase progression in cell cycle. The mechanisms may be related to the upregulation of eNOS mRNA and the increase of the formation of NO and cGMP.
人参皂苷 Rg1(Rg1)已被报道可抑制血管平滑肌细胞(VSMC)的增殖。本研究旨在观察一氧化氮(NO)在 Rg1 抗增殖作用中的作用。采用组织块法培养 SD 大鼠胸主动脉 VSMC,用 MTT 法评价 Rg1(20mg·L(-1)、60mg·L(-1)和 180mg·L(-1))对血小板衍生生长因子-BB(PDGF-BB)诱导的增殖作用。用流式细胞术分析细胞周期。通过一氧化氮试剂盒和 cGMP 放射免疫试剂盒分别测定上清液中 NO 的含量和 VSMCs 中环鸟苷酸(cGMP)水平,用实时 RT-PCR 检测 VSMCs 原癌基因 c-fos 和内皮型一氧化氮合酶(eNOS)mRNA 的表达,用 Fura-2/AM 负载的 VSMCs 检测细胞内游离钙浓度(Ca2+)。与正常组相比,Rg1 180mg·L(-1)不改变正常细胞的 MTT 吸光度和 G0/G1、G2/M 和 S 期细胞百分比(P > 0.05)。相反,PDGF-BB 可增加 MTT 的吸光度(P < 0.01)和 S 期细胞的百分比,但降低细胞周期中的 G0/G1 期细胞百分比,同时上调 c-fos mRNA 表达(P < 0.01),而添加 Rg1(20mg·L(-1)、60mg·L(-1)和 180mg·L(-1))可逆转上述作用。与单独用 PDGF-BB 处理的组相比,Rg1 给药还可显著增加上清液中 NO 含量和 VSMCs 中环鸟苷酸(cGMP)水平,以及细胞中 eNOS mRNA 的表达(P < 0.01)。此外,Rg1 可进一步增加 PDGF-BB 诱导的升高的Ca2+。综上所述,Rg1 可通过限制细胞周期中 G0/G1 期向 S 期的进展来抑制 PDGF-BB 诱导的 VSMC 增殖。其机制可能与 eNOS mRNA 的上调和 NO 和 cGMP 的形成增加有关。